Endomyocardial biopsy remains the gold standard for monitoring heart transplant rejection, though new, less invasive diagnostic methods like gene expression profiling reduce the number of biopsies required.
While endomyocardial biopsy remains the gold standard for diagnosing heart transplant rejection, emerging non-invasive methods are increasingly utilized to reduce the frequency of invasive biopsies.
Heart transplant prolongs life for patients with end-stage heart failure but rejection remains a complication that reduces long-term survival. The aim is to provide a comprehensive overview of the current status in HT rejection. EMB is an invasive diagnostic tool, consisting in the sampling of a fragment of myocardial tissue from the right ventricular septum using fluoroscopic guidance. This tissue can later be subjected to histopathological, immunohistochemical or molecular analysis, providing valuable information for cardiac allograft rejection, but this procedure is not without complications. To increase the accuracy of the rejection diagnosis, EMB requires a systematic evaluation of endocardium, myocardium, interstitium and intramural vessels. There are three types of rejection: hyperacute, acute or chronic, diagnosed by the histopathological evaluation of EMB as well as by new diagnostic methods such as DSA, ddcfDNA and gene expression profiling, the last having a high negative predictive value. More than 50 years after the introduction of EMB in medical practice, it still remains the "gold standard" in monitoring rejection in HT recipients but other new, less invasive diagnostic methods reduce the number of EMBs required.
Farcas et al. (Thu,) conducted a review in Heart transplant rejection. Endomyocardial biopsy and non-invasive diagnostic methods was evaluated. Endomyocardial biopsy remains the gold standard for monitoring heart transplant rejection, though new, less invasive diagnostic methods like gene expression profiling reduce the number of biopsies required.